Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Nanobiotix (NBTX) Stock Price & Analysis

NBTX Stock Chart & Stats

$28.42-$2.95(-9.40%)
At close: 11:15 AM EST
$20$30$4010 Aug24 Aug8 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
$27.49 - $30.46
52-Week Range
$17.42 - $57.14
Previous Close
$31.37
Volume
N/A
Average Volume (3M)
141.80K
Market Cap
$1.60B
Enterprise Value
$1.84B
Total Cash (Recent Filing)
$110.85M
Total Debt (Recent Filing)
$106.57M
Price to Earnings (P/E)
―
Beta
0.88
Next Earnings
Apr 27, 2027 (Est.)
EPS Estimate
0.06
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy Potential

The melanoma results provide clinical evidence that NBTXR3 may generate meaningful responses in heavily pre-treated, anti-PD-1-resistant patients. The observed activity, safety profile, and immune findings support advancing the program into randomized trials and could broaden its therapeutic and partnering potential.

Strategic Partnership Economics

The Janssen relationship gives Nanobiotix access to a major pharmaceutical partner for development and commercialization while preserving potential milestone, royalty, or profit-sharing upside. This partnership model can reduce commercialization demands and create important future funding sources if programs advance.

Revenue Rebound

The sharp 2025 revenue rebound indicates that partnership-related economics can produce substantial inflows when contractual or development activity improves. Although the history is volatile, higher revenue demonstrates commercial monetization potential beyond a purely pre-revenue clinical-stage profile.

Bears Say

Persistent Unprofitability

Nanobiotix has not yet demonstrated a sustainable profit model despite the recent revenue recovery. Continuing operating and net losses mean future growth still depends on clinical execution and external funding, while prolonged losses can constrain investment capacity and weaken financial resilience.

Weak Balance Sheet

Negative equity and debt exceeding total assets indicate materially weakened capitalization and limited financial flexibility. This balance-sheet structure can make it harder to absorb setbacks, secure funding on attractive terms, or sustain development investment without additional financing or partnership support.

Ongoing Cash Burn

Persistent negative operating and free cash flow shows that the current business does not fund its own operations. Nanobiotix therefore remains dependent on external capital, collaboration proceeds, or future milestones to maintain clinical development, increasing funding pressure over the next several quarters.

Nanobiotix News

NBTX FAQ

What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $17.42 and its highest was $57.14 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $1.60B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s next earnings report is estimated for Apr 27, 2027 (not yet confirmed), which is in 175 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Sep 24, 2026. The company reported -$0.784 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.494.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is 0.06.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,967,610 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -$0.784 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -0.448%.
Which hedge fund is a major shareholder of Nanobiotix?
Hedge funds hold Nanobiotix shares: the largest hedge-fund position in Nanobiotix is 63,558,009 shares, and hedge funds decreased their holdings by 105.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology